Ligand Pharmaceuticals (LGND)
(Delayed Data from NSDQ)
$73.90 USD
+1.58 (2.18%)
Updated May 3, 2024 04:00 PM ET
After-Market: $73.99 +0.09 (0.12%) 7:58 PM ET
1-Strong Buy of 5 1
D Value D Growth D Momentum D VGM
Price, Consensus and EPS Surprise
LGND 73.90 +1.58(2.18%)
Will LGND be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for LGND based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for LGND
Ultragenyx (RARE) Q1 Loss Wider Than Expected, Revenues Rise Y/Y
Agios (AGIO) Q1 Earnings Surpass, Sales Miss Estimates
LGND: What are Zacks experts saying now?
Zacks Private Portfolio Services
Puma Biotechnology's (PBYI) Q1 Earnings and Revenues Beat
Blueprint (BPMC) Q1 Earnings and Revenues Beat, Stock Rises
Zoetis (ZTS) Q1 Earnings and Revenues Surpass Estimates
Other News for LGND
See How Ligand Pharmaceuticals Ranks Among Analysts' Top Picks With Strong Buyback Activity
Ligand: Buy This Pharma Royalty Aggregator To Generate Growth In Your Portfolio
Tourlite Capital Q1 2024 Investor Letter
Ligand to Report First Quarter 2024 Financial Results on May 7, 2024
Ligand Pharma (LGND) Gets a Buy from Barclays